Events List
Discover conferences, symposia and other events worldwide.
View monthly calendar
Submit your event
327 event(s) found
I Summit de Oncohematogeriatria
In Portuguese: "O Brasil vive um novo tempo: a revolução da longevidade já começou, e com ela surgem desafioos complexos — e oportunidades extraordinárias. É nesse cenário que nasce o I Summit de Oncohematogeriatria, uma iniciativa pioneira e inédita no Brasil, primeiro evento nacional dedicado exclusivamente ao cuidado oncohematológico da pessoa idosa, com abordagem distinta da oncogeriatria tradicional. Um espaço que integra especialistas e práticas baseadas em evidências para discutir os avanços e desafios na interface entre hematologia, oncologia e geriatria. A ser realizado em Belém do Pará, pós COP30, o Summit será um marco na construção de um cuidado mais integral, inovador e humanizado. Com o tema: “Fragilidade, inovação terapêutica e reabilitação: o tripé do cuidado oncohematológico na pessoa 60+”, o evento reunirá especialistas de renome nacional e internacional com o apoio de instituições comprometidas com o avanço da ciência e da prática clínica. Mais do que um evento técnico, o Summit será um espaço de conexão, reflexão e transformação, onde serão discutidas não apenas as terapias mais modernas — como CAR-T cells, anticorpos biespecíficos e o papel da avaliação de fragilidade na decisão terapêutica —, mas também os valores que sustentam o cuidado ético e personalizado no envelhecimento."
04/06/2026 - 05/06/2026
In-person
SBGG - PA
Belém, Pará, Brazil
Hangar Centro de Convençǒes da Amazônia
SIFEM 2026 - Osons repenser les dogmes
In French: "Ce congrès sera l’occasion de revisiter les dogmes en imagerie du sein et du pelvis, de confronter les idées reçues aux données les plus récentes, et de proposer des alternatives éclairées aux paradigmes établis." Nous aborderons des sujets très pratiques, partagerons nos difficultés et discuterons ensemble des pièges rencontrés au quotidien dans notre pratique de l’imagerie de la femme, qu’il s’agisse de la pertinence des examens, de l’intégration de l’intelligence artificielle ou d’une meilleure anticipation des défis cliniques, technologiques et organisationnels auxquels nous faisons face chaque jour."
04/06/2026 - 04/06/2026 In-person SIFEM Montpellier, France Corum
Kadans Oncology Summit 2026
A major international event, the Kadans Oncology Summit will bring together leading stakeholders from research, innovation, industry and public authorities. This day will mark a significant milestone with the official launch of Campus Grand Parc, the first biocluster in France anchored by Paris Saclay Cancer Cluster (PSCC). Program highlights: · Keynote presentation by Eric Vivier (President of PSCC) and Fabrice Barlesi (CEO of Gustave Roussy); · Roundtable discussions with VC, Big Pharma companies and biotech representatives; · B2B meetings and exchanges; · Grand opening ceremony with many surprises in store.
04/06/2026 - 04/06/2026 In-person Kadans Science Partner, France 2030, Medicen Paris Région, PSCC, Région Île-de-France Villejuif, France The HIVE, Campus Grand Parc 
EACR 2026 Congress
The 2026 Annual Congress of the European Association for Cancer Research (EACR 2026) is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.
07/06/2026 - 10/06/2026 In-person EACR Budapest, Hungary HungexpoSymposium iTOX 2026
In French: "Le symposium ITOX 2026 réunit des experts nationaux et internationaux pour aborder les toxicités liées aux immunothérapies en cancérologie, avec un focus particulier sur les effets indésirables des inhibiteurs de points de contrôle immunitaires et des thérapies cellulaires (CAR-T, T-cell engagers). Le programme comprend : - Sessions éducatives en français : "Nouvelles" immunothérapies antitumorales Toxiciés des ADC / immunoconjugués cytotoxiques Evolution des prises en charges Pièges diagnostiques - Discussion de cas cliniques complexes Points de vue des patient.es sur les effets indésirables immuno-médiés - Sessions orales en anglais : Cellular therapies Keynote lecture Dissecting the mechanism of … Immunosuppressive drugs Cet événement est un lieu privilégié d’échanges interdisciplinaires entre oncologues, immunologistes, internistes, chercheurs et cliniciens impliqués dans la prise en charge des patients traités par immunothérapies."
08/06/2026 - 09/06/2026 In-person Gustave Roussy Le Kremlin-Bicêtre, France Faculté de médecine, Université Paris-Saclay
5th World ADC Summit South Korea
Innovating Novel Payload, Dual Payload & Bispecific ADCs to Drive Platform Differentiation that Combats Resistance & Accelerates more ADCs to First & Best-in Class Drugs The need to move away from biosimilars and innovate novel technologies, has taken the ADC field in South Korea by storm. With novel payloads, dual payloads, and bispecific ADCs taking the center stage, Korean developers are now focused on overcoming Topo 1 ADC challenges to first-in-class ADCs and maximizing success to improve their partnership opportunities with big pharma. With this in mind, the 5th World ADC Summit South Korea (previously World ADC Asia) is returning to provide you with the most comprehensive platform for South Korea’s rapidly growing ADC community. Join the likes of Daiichi Sankyo, Astellas, Gilead, AbbVie, Kanaph Therapeutics, OBI Pharma, Aimed Bio, Huadong Medicine, and more, for end-to-end insights on the evolving ADC landscape, novel technologies, dual payloads, and bispecific ADCs to further your ADC development. Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on targeted protein degradation (TPDs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
09/06/2026 - 11/06/2026 In-person Hanson Wade Seoul, South Korea COEX Magok Lewest
World TPD & Induced Proximity Summit South Korea
With the first anticipated PROTAC approval and multiple candidates advancing through clinical trials, 2026 is going to be a pivotal year for the global targeted-protein degradation (TPD) industry. This global momentum is fueling Korea’s own TPD boom: over $144M raised in the past 12 months, alongside strategic collaborations from leaders like Ubix Therapeutics, Prazer Therapeutics, and Bridge Biotherapeutics. The inaugural World TPD & Induced Proximity Summit South Korea is the only event dedicated to gathering the Asian biopharma focused on end-to-end TPD drug development. Featuring key international opinion leaders, deep dives into preclinical and clinical strategy, and expanded content on molecular glues and novel E3 ligases, this summit is your chance to de-risk your pipelines, learn from international experts, and build the global collaborations needed to advance best-in-class TPD therapeutics. Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
09/06/2026 - 11/06/2026 In-person Hanson Wade Seoul, South Korea COEX Magok Lewest
World Bispecific & T-Cell Engager Summit South Korea
Bispecifics and T-cell engagers are redefining the future of solid tumor treatment. With the landmark approvals of tarlatamab and ivonescimab, the spotlight is firmly on these modalities as powerful solutions for long-standing unmet needs. At the same time, the field is rapidly evolving beyond first-generation designs, with innovations in co-stimulation, conditional activation, multispecific engineering, and affinity tuning aimed at deepening response rates while mitigating dose-limiting toxicities. Innovation is rife within Korea, with companies such as ABL Bio, Novelty Nobility, ABION, and IM Biologics capturing international attention and investment, positioning Korea as a key player in the bispecific and TCE revolution. To accelerate this momentum, the inaugural World Bispecific & T-Cell Engager Summit South Korea comes as the only event in Asia dedicated to bringing together biopharma professionals focused on the discovery and development of differentiated Bispecifics and T-cell engagers that could become first-in-class therapies. Featuring key international opinion leaders, the agenda will deep dive into co-stimulation techniques, conditional activation, affinity window engineering, and bispecific ADCs (bsADCs), spotlighting cutting-edge strategies to expand the therapeutic window, overcome antigen escape, reduce CRS, and improve clinical predictability. As part of the World Targeted Therapeutics Summit South Korea, organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), targeted protein degradation, and induced proximity, which aim to turn South Korea into the next global hub for biopharma innovation in targeted therapeutics. From discovery to manufacturing, you’ll get end-to-end coverage to equip your entire team with the insights needed to innovate and differentiate, ultimately attract interest for global pharma partnerships.
09/06/2026 - 11/06/2026 In-person Hanson Wade Seoul, South Korea COEX Magok Lewest
EHA2026 Congress
EHA2026 will once again offer an exceptional scientific program, featuring a seamless flow of engagement across Plenary Sessions—including the Opening Ceremony, Plenary Abstracts Session, and Presidential Sessions—alongside carefully curated Sponsor Symposiums spread throughout each Congress day.
10/06/2026 - 13/06/2026 In-person EHA Stockholm, Sweden StockholmsmässanIntratumoral Immunotherapy Symposium 2026
This intensive two-day training program, jointly organized by Gustave Roussy, is dedicated to intratumoral immunotherapy—an innovative therapeutic approach aimed at stimulating the immune response directly within tumors. Participants will gain a comprehensive understanding of the fundamental principles, historical evolution, and most recent clinical developments in this rapidly advancing field. The program combines scientific lectures, clinical case studies, innovative drug delivery technologies, and discussions on regulatory and operational aspects. Sessions will also include interactive panel discussions, fostering exchanges on current challenges and future perspectives in intratumoral immunotherapy.
11/06/2026 - 12/06/2026 In-person Gustave Roussy Villejuif, France Event Room, La Ruche, The HIVE
Immunity for Health Symposium 2026
Focusing on innovations in antibody-based biologics, the event will bring together leading researchers, biotech innovators, and industry experts to explore the latest advances in next-generation antibody technologies for diagnostics and immunological therapies, while fostering collaboration and discussing future directions in the field. Key discussions will cover: · Novel antibody technologies · Precision imaging approaches · Nanobody bispecifics · Monoclonal antibodies for companion animals · Clinical translation challenges
11/06/2026 - 11/06/2026 In-person Immunity for Health Jette, Belgium Landmark building, UZ Brussels
SFCO : Congrès 2026
In French: "Face aux mutations rapides de notre environnement – innovations technologiques, évolutions thérapeutiques, attentes accrues en termes de qualité et de personnalisation des soins – la chirurgie oncologique se trouve à un tournant. Ce congrès se veut le lieu de la réflexion collective, de l’audace scientifique et du partage d’expertise. Durant ces deux journées, nous aurons l’occasion d’explorer les enjeux majeurs à venir : progrès technologiques, prise en charge multidisciplinaire, adaptation des pratiques aux nouvelles réalités, et maintien de l’excellence chirurgicale pour servir au mieux nos patients."
11/06/2026 - 12/06/2026 In-person SFCO Lyon, France L’Embarcadère
6ème Journée de l’innovation en cancérologie pulmonaire
In French: "La journée consacrée aux Innovations dans le traitement du Cancer Pulmonaire est de retour."
12/06/2026 - 12/06/2026 In-person Hôpital Cochin, AP-HP, Université Paris Cité, CARPEM Paris, France Hôpital Cochin
EORTC-ESMO-AACR Methods in Clinical Cancer Research Workshop
The annual Methods in Clinical Cancer Research Workshop (MCCR) is a week-long course designed to educate and train early-career investigators in the best practices of clinical trial design and provide access to experienced clinical investigators from different institutions and countries with expertise across all areas of clinical research.
13/06/2026 - 18/06/2026 In-person EORTC, ESMO, AACR Sint-Michielsgestel, Netherlands Hotel de l’Europe Target Innovation & Novel Screening Technologies
We’re partnering with Oxford Global to host an ELRIG scientific track as part of their Drug Discovery Europe 2026 conference.
15/06/2026 - 15/06/2026 In-person ELRIG, Oxford Global Berlin, Germany Estrel Congress Centre
Drug Discovery Europe - Part of Discovery & Development Europe 2026
Join world-leading experts at our annual Drug Discovery, Neuroscience Drug Development, and Automation & AI & Data programmes—showcasing bold strategies, breakthrough science, and cutting-edge technologies in target discovery, medicinal chemistry, and drug design. Gain fresh insights from case studies on PROTACs, ADCs, molecular glues, and the power of AI-driven tools in early R&D. Discover advances in tackling neuroscience and age-related diseases, strategies to cross the blood–brain barrier, and the data-driven digital tech transforming discovery workflows.
15/06/2026 - 15/06/2026 In-person Oxford Global Berlin, Germany Estrel Congress Centre
Drug Discovery USA 2026: Emerging multifunctional small molecule and biologic approaches to drug difficult targets
Recent advances in chemical biology and protein engineering are expanding the boundaries of which proteins can be modulated pharmacologically. Multifunctional small molecules (such as molecular glues, targeted protein degraders, and allosteric modulators) are enabling precise control over protein stability, localization and activity, often by exploiting endogenous cellular pathways. In parallel, novel biologic modalities, including engineered antibodies, multi-specific binders, peptide scaffolds, nucleotide and RNA therapeutics, offer complementary strategies to engage complex or transient target surfaces with high affinity and specificity. Collectively, these approaches are reshaping early‑stage drug discovery by providing versatile platforms to modulate challenging targets through mechanisms beyond simple inhibition. Furthermore, hybrid strategies that integrate small molecules with biologics, such as antibody–drug conjugates (ADCs) and chemically enhanced biologics, are demonstrating synergistic potential. Together, these emerging technologies highlight a rapidly evolving therapeutic landscape in which difficult to drug targets are increasingly accessible, opening new avenues for disease intervention and precision medicine. Continued innovation in molecular design, delivery, and mechanistic understanding will be critical to fully realize the promise of these next‑generation modalities.
16/06/2026 - 17/06/2026 In-person ELRIG Boston, MA, United States Pfizer (Research & Manufacturing site)
IFODS - Le Congrès National d'Oncologie
Featuring the Best of ASCO 2026 (officially licensed), "Onco Startup" pitches and more, across solid tumors and hemato-oncology.
17/06/2026 - 19/06/2026 Hybrid IFODS Paris, France Centre de Conférences Novotel Tour Eiffel21ème Journées GSF-GETO
21ème Journées GSF-GETO organized by GSF
17/06/2026 - 19/06/2026 In-person GSF Reims, France TBD Cell Symposia: Multifaceted mitochondria
Cell Symposia: Multifaceted mitochondria organized by Cell (Elsevier Ltd.)
21/06/2026 - 23/06/2026 In-person Cell (Elsevier Ltd.) Glasgow, Scotland, United Kingdom TBD
2nd AI in Oncology Paris - PRISM Institute
Following the success of the first edition, which brought together over 400 participants in Paris in June 2025, we are delighted to announce the return of the AI in Oncology Conference by IHU PRISM, taking place on June 22–23, 2026, at the Novotel Paris Tour Eiffel: An international conference dedicated to advancing the application of artificial intelligence in cancer care and research. The 2025 edition enabled participants to delve into key aspects of AI in Oncology including radiology, digital pathology, generative models, multiomics and precision oncology trials. In 2026, we will build on this momentum by broadening our scope to include the latest developments and real-world applications of AI that are transforming oncology today. Beyond the scientific content, AI in Oncology Conference by IHU PRISM will once again serve as a unique platform to exchange ideas, share experiences, and foster collaborations among clinicians, researchers, data scientists, and industry experts shaping the future of personalized cancer care.
22/06/2026 - 23/06/2026 In-person PRISM Institute Paris, France TBD
Imaging, Omics and AI in Single Cell Biology Symposium
Understanding tumor biology requires approaches capable of capturing molecular states, spatial organization, and dynamic behavior at single-cell resolution. This one-day symposium brings together researchers working in omics, advanced imaging, and artificial intelligence to explore how the integration of these complementary technologies can transform single-cell biology and cancer research. The program will highlight emerging and state-of-the-art technologies in genomics, transcriptomics, proteomics, live-cell and spatial imaging, as well as machine-learning approaches. There will be ample opportunities for PhD students and postdoctoral researchers to present their latest work, with preference given to studies that integrate these technologies to move beyond descriptive atlases toward a predictive, mechanistic understanding of fundamental tumor biology, including tumor development, tumor microenvironment, tumor heterogeneity and plasticity, and therapy response. The symposium is organized by Oncode Institute and is open to both Oncode and non-Oncode researchers, with the aim of fostering cross-disciplinary exchange and catalyzing new collaborations across the single-cell and cancer research communities.
23/06/2026 - 23/06/2026 In-person Oncode Institute Utrecht, Netherlands Accelerator building, Utrecht Science Park Advances in Malignant Lymphoma: From Discovery to Clinical Impact
The fifth Advances in Malignant Lymphoma: From Discovery to Clinical Impact conference, held in cooperation with the International Conference on Malignant Lymphoma (ICML), will convene experts from academia, industry, government, and foundations to examine how molecular mechanisms and translational research are driving therapeutic progress. The program will highlight advances in understanding germinal center biology and beyond, lymphoma origins and classifications, including rare and aggressive subtypes, and microenvironmental influences, that define disease behavior and therapeutic response. This conference is uniquely positioned to integrate scientific discoveries across epigenetics, disease modeling, and computational biology with emerging therapeutic advances in antibody evolution, next-generation clinical assessment, degraders, and cellular therapies. Together, these efforts will capture the entire spectrum of lymphoma research and drive progress toward improved patient outcomes.
24/06/2026 - 27/06/2026 In-person AACR Philadelphia, PA, United States Philadelphia Convention Center Prague Metabolism and Signaling Symposium
Prague Metabolism and Signaling Symposium organized by Prague Metabolism Symposium
24/06/2026 - 27/06/2026 In-person Prague Metabolism Symposium Prague, Czech Republic TBD